Intercept Pharmaceuticals Inc (NASDAQ:ICPT), a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat neglected chronic liver diseases, announced …
Intercept Pharmaceuticals Inc (NASDAQ:ICPT) (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat neglected chronic liver diseases, …
Intercept Pharmaceuticals Inc (NASDAQ:ICPT) shares climbed almost 10 percent in the last two days after the company’s competitor Genfit announced that its drug GFT505 had failed …
Intercept Pharmaceuticals Inc (NASDAQ:ICPT) received another set of praises from analysts at Wedbush in a research note released today. The research team, led by analyst …
Intercept Pharmaceuticals Inc (NASDAQ: ICPT) is a biopharmaceutical company known for developing drug treatments for chronic liver diseases. The company’s current leading drug is …
In a research report released Monday, Needham analyst Alan Carr reiterated a Buy rating on Intercept Pharmaceuticals Inc (NASDAQ:ICPT) with a price target of …
Intercept Pharmaceuticals Inc (NASDAQ:ICPT) shares are up 2.46% today, as the company will present two poster presentations highlighting new subgroup analyses from the Phase 2b FLINT trial …
In a research report published after market close today, MLV & Co. analyst Vernon Bernardino initiated coverage on shares of Intercept Pharmaceuticals Inc (NASDAQ:ICPT) with …
In a research report released on March 11, Oppenheimer analyst Akiva Felt maintained an Outperform rating on Intercept Pharmaceuticals Inc (NASDAQ:ICPT) before new Phase …
In a research report issued today, Wedbush analyst Liana Moussatos reiterated an Outperform rating on Intercept Pharmaceuticals Inc (NASDAQ:ICPT), with a price target of $493, following the …
